AerWave made an announcement today about successfully completing its initial human feasibility study for its innovative ultrasound-based lung denervation therapy, aimed at modifying disease progression.
Hailing from New York, AerWave has also managed to secure $12 million in funding to propel its treatment aimed at chronic obstructive pulmonary disease (COPD) and asthma.
The ultrasound technology is designed to streamline and improve the lung denervation process, as stated in a press release. Substituting the requirement for fluoroscopic guidance, esophageal marker balloons, and multiple catheter exchanges, the method delivers exact circumferential ablation with a single application of energy, targeting the core causes of the disease and not merely the symptoms.
According to AerWave, their technology offers accuracy in treatment with a straightforward, singular ablation procedure, effectively avoiding sensitive regions such as peri-esophageal nerves. This concise procedure includes a one-time, circumferential method, thereby doing away with fluoroscopy and extra equipment by using a universal catheter suitable for varied airway structures.
Beyond lung denervation, the AerWave platform expands its capabilities to include targeted lung tumor ablation and reducing lung volume. Thanks to ultrasound’s precision in energy application while avoiding unnecessary treatments, the company believes this opens doors for additional clinical uses.
“Successfully concluding our first-in-human trial, coupled with our newly secured funds, marks significant progress for our team,” commented Patrick Gallagher, CEO of Aerwave Medical. “Our technology tackles pressing issues in respiratory care and presents a scalable, disease-modifying solution that holds promise for enhancing patient outcomes.”